Actual consolidation treatment according to PET-driven strategy in both randomization groups
| Actual consolidation treatment . | R-ACVBP 14 (n = 103) . | R-CHOP 14 (n = 97) . | All (n = 200) . | |||
|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | |
| PET2−/PET4− | ||||||
| All (n) | 28 | 24 | 52 | |||
| R-chemotherapy | 28 | 100 | 23 | 96 | 51 | 98 |
| High dose therapy + ASCT | 0 | 1 | 4 | 1 | 2 | |
| PET2+/PET4− | ||||||
| All (n) | 30 | 18 | 48 | |||
| High dose therapy + ASCT | 25 | 83 | 15 | 83 | 40 | 83 |
| R-chemotherapy | 5 | 17 | 3 | 17 | ||
| PET4+ | ||||||
| All (n) | 45 | 55 | 100 | |||
| Salvage therapy | 28 | 62 | 38 | 69 | 66 | 66 |
| Salvage therapy followed by ASCT | 21 | 47 | 25 | 45 | 46 | 46 |
| Salvaged not followed by ASCT | 7 | 15 | 13 | 24 | 20 | 20 |
| High dose therapy + ASCT | 17 | 38 | 16 | 29 | 33 | 33 |
| R-chemotherapy | 0 | 1 | 2 | 1 | 1 | |
| Actual consolidation treatment . | R-ACVBP 14 (n = 103) . | R-CHOP 14 (n = 97) . | All (n = 200) . | |||
|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | |
| PET2−/PET4− | ||||||
| All (n) | 28 | 24 | 52 | |||
| R-chemotherapy | 28 | 100 | 23 | 96 | 51 | 98 |
| High dose therapy + ASCT | 0 | 1 | 4 | 1 | 2 | |
| PET2+/PET4− | ||||||
| All (n) | 30 | 18 | 48 | |||
| High dose therapy + ASCT | 25 | 83 | 15 | 83 | 40 | 83 |
| R-chemotherapy | 5 | 17 | 3 | 17 | ||
| PET4+ | ||||||
| All (n) | 45 | 55 | 100 | |||
| Salvage therapy | 28 | 62 | 38 | 69 | 66 | 66 |
| Salvage therapy followed by ASCT | 21 | 47 | 25 | 45 | 46 | 46 |
| Salvaged not followed by ASCT | 7 | 15 | 13 | 24 | 20 | 20 |
| High dose therapy + ASCT | 17 | 38 | 16 | 29 | 33 | 33 |
| R-chemotherapy | 0 | 1 | 2 | 1 | 1 | |